Overview

Valor Medical™ is a Delaware, C-Corp that has developed a device to treat cerebral aneurysms, arteriovenous malformations (AVMs) and as a treatment for coil salvage (patients who have had their aneurysm treated with endovascular coils in whom, on follow-up, the coil treatment has failed). The proprietary and patent pending device, Neucrylate™, is a new derivative of a cyanoacrylate monomer that will polymerize on contact with blood. Neucrylate is injected through a micro-infusion catheter that the surgeon positions inside of the cerebral aneurysm. Neucrylate begins as a low viscosity liquid but when it comes in contact with endothelium or blood, it changes into a firm, open pore sponge like material. Pre-clinical data documents that the porous sponge like material allows tissue in-growth into the aneurysm and over the aneurysm neck.

Valor Medical's first product, Neucrylate A™, will be indicated for the treatment of cerebral berry aneurysm, plus for failed coil salvage. A second-generation product will be developed to treat AVMs.

Valor Medical has begun treating patients outside the United States under a clinical trial protocol. The Company expects to begin European sales by early 2010. Valor has submitted an IDE to the FDA and is in discussions with the FDA for approval to begin trials in the United States.

Industry analyst estimate that the cerebral aneurysm market will grow at a rate of ~20%,
from $267 million in 2005 to $920 million in 2012. Valor’s Neucrylate is expected to reach sales of $91 million in 2012.